Charles (Chuck) Kummeth
President and Chief Executive Officer
Charles Kummeth became President and Chief Executive Officer of Techne Corporation on April 1, 2013. Prior to joining the Company, he served as President of Mass Spectrometry and Chromatography at Thermo Fisher Scientific Inc. and was President of that company's Laboratory Consumables Division from 2009 to September 2011. Prior to joining Thermo Fisher, Mr. Kummeth served in various roles during his 24 year career at 3M Corporation, most recently as the Vice President of the company's Medical Division from 2006 to 2008.
Mr. Kummeth received a Master of Science in Computer Science from the University of St. Thomas and a Master of Business Administration from the Carlson School of Business at the University of Minnesota. He is a graduate of the University of North Dakota, where he received a Bachelor of Science in Electrical Engineering. Mr. Kummeth serves on the boards of Sparton and Avantor.
Chief Financial Officer
James T. Hippel became Chief Financial Officer on April 1, 2014. Prior to joining the Company, he served as Senior Vice President and CFO for Mirion Technologies, Inc., a $300 million global technology and manufacturing company which provides mission critical products to detect, monitor and identify radiation. Prior to Mirion, Mr. Hippel served as Vice President, Finance at Thermo Fisher Scientific, Inc., leading finance operations for its $2 billion Mass Spectrometry & Chromatography and $1 billion Laboratory Consumables divisions. Mr. Hippel's experience also includes nine years of progressive financial leadership at Honeywell International, within its Aerospace Segment. He began his career with KPMG Peat Marwick LLP. Mr. Hippel holds a Masters in Business Administration from Arizona State University and a Bachelor of Accountancy degree from Northern Arizona University. He is also a CPA (inactive).
J. Fernando Bazan, Ph.D
Chief Technology Officer
Dr. J. Fernando Bazan was appointed Chief Technology Officer when he joined the Company on August 1, 2013. Following training at Stanford, Berkeley, and UCSF in biochemistry and biophysics, he led very active groups in biotherapeutics discovery as a senior scientist at DNAX Research Institute (now Merck Research Labs) and at Genentech (Roche). He also served as Chief Scientific Officer at NeuroScience, a neuroimmunology diagnostics startup. Dr. Bazan holds an adjunct faculty appointment in the Dept. of Pharmacology at the University of Minnesota School of Medicine.
Senior VP, Biotech Division
Dave Eansor was appointed Senior Vice President of the Biotech Division in April 2015. Prior to that Mr. Eansor was Senior Vice President, Novus Biologicals, after the Company's acquisition of Novus Biologicals in July, 2014. Prior to joining Novus Biologicals in 2013, Mr. Eansor was the President of the Bioscience Division of Thermo Fisher Scientific. Mr. Eansor was promoted to Division President in early 2010 after 5 years as President of Thermo Fisher's Life Science Research business.
Senior VP and General Counsel
Brenda Furlow joined the Company as Senior Vice President and General Counsel in August, 2014. Before joining the Company, Ms. Furlow was affiliated with Alphatech Counsel, SC and served as general counsel to emerging growth technology companies. From 2007 to 2011, Ms. Furlow was General Counsel for TomoTherapy, Inc., a global, publicly traded company that manufactured and sold radiation therapy equipment, and from 1998 to 2007, she was General Counsel for Promega Corporation, a global life sciences company, Ms. Furlow holds a Juris Doctor degree from University of Chicago Law School.
Senior VP, Protein Platforms Division
Bob brings nearly 20 years of experience to the ProteinSimple development team. Most recently, he served as Director of Engineering at MDS Analytical Technologies (previously Molecular Devices, Inc.), where he directed multidisciplinary teams of mechanical, electrical, firmware, and systems engineers. Bob has a strong record of creating highly successful laboratory systems, including industry-leading optical plate readers and high throughput screening platforms. Prior to Molecular Devices, he managed a team of engineers at Affymax Research Institute, developing automated peptide and small molecule synthesis and compound-handling instruments. Bob holds a B.S. in Mechanical Engineering and an M.S. in Manufacturing Systems Engineering from Stanford University.
Senior VP, Diagnostics Division
Kevin Gould became SVP Diagnostics Division on January 1, 2016. He brings over 15 years of senior management experience principally in medical diagnostics manufacturing. Prior to joining
Bio-Techne he held senior level positions including President and CEO, Cliniqa; Vice President, SeraCare BBI Diagnostics business unit of SeraCare Life Sciences, Inc.; and Vice President, Sales & Marketing for Medical Analysis Systems Inc., now part of Thermo Fisher Scientific Inc. Additional positions were held with Biopool International, now part of Trinity Biotech PLC, and Curtin Matheson Scientific Inc., now Thermo Fisher Scientific Inc.